Palonosetron

Patient w/ history of constipation, intestinal obstruction, history or risk of QT interval prolongation, electrolyte abnormalities. Childn. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, somnolence or fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs and symptoms of serotonin syndrome.

Significant: QT prolongation, bradycardia, hypersensitivity reactions (e.g. anaphylaxis). Nervous: Headache, dizziness, somnolence, fatigue, weakness, anxiety, vertigo, flu-like symptoms, insomnia, paresthesia. CV: Nonsustained tachycardia, hypotension, HTN, MI, hot flush. GI: Constipation, diarrhoea, abdominal pain, dyspepsia, dry mouth, hiccups, flatulence, anorexia. Hepatic: Increased serum ALT/AST, bilirubin. Genitourinary: Urinary retention. Endocrine: Hyperkalaemia, electrolyte fluctuations, hyperglycaemia, metabolic acidosis, glycosuria. Musculoskeletal: Arthralgia. Ophthalmologic: Amblyopia. Otic: Tinnitus. Dermatologic: Pruritus, rash, allergic dermatitis. Others: Inj site reaction.
Potentially Fatal: Rarely, serotonin syndrome (e.g. altered mental status, autonomic instability, neuromuscular symptoms).

Decreased therapeutic effect of tramadol.

Antiemetics / Supportive Care Therapy

A04AA05 - palonosetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.